Abacavir is an antiretroviral drug widely studied in pharmacology, medicinal chemistry, pharmaceutical sciences, and HIV research. It belongs to the nucleoside reverse transcriptase inhibitor, or NRTI, class of medicines. From an academic perspective, abacavir is especially interesting because the administered drug is converted inside cells into an active metabolite that interferes with HIV reverse transcriptase.
Understanding abacavir involves more than memorising its drug class. Students should know its chemical identity, mechanism of action, active metabolite, development history, generic and trade names, and pharmacopoeial significance.
NCBI PubChem identifies abacavir as a synthetic carbocyclic nucleoside analogue with the molecular formula C14H18N6O and a molecular weight of 286.33 g/mol. Its PubChem Compound ID is 441300.
This academic overview explains abacavir in a structured way using information from NCBI, PubMed, NIH ClinicalInfo, and the Indian Pharmacopoeia Commission. It is intended for students, researchers, educators, and healthcare learners who want a reliable foundation for further study.
Abacavir at a Glance
The following table summarises the most important academic identifiers of abacavir.
| Generic Name | Abacavir |
| Drug Class | Nucleoside Reverse Transcriptase Inhibitor (NRTI) |
| Abbreviation | ABC |
| Molecular Formula | C14H18N6O |
| Molecular Weight | 286.33 g/mol |
| PubChem CID | 441300 |
| CAS Number | 136470-78-5 |
| Common Salt Form | Abacavir Sulphate |
| Trade Name Example | Ziagen |
What Is Abacavir?
Abacavir is a synthetic antiretroviral compound classified as a nucleoside analogue reverse transcriptase inhibitor. It is also described as a synthetic carbocyclic nucleoside analogue.
NCBI describes abacavir as a 2,6-diaminopurine derivative and identifies it as an inhibitor of HIV-1 reverse transcriptase.
The Indian Pharmacopoeia Commission includes Abacavir Sulphate as a pharmacopoeial substance and reference material, highlighting its importance in pharmaceutical identification, analysis, and quality control.
Abacavir Classification and Mechanism of Action
Pharmacological Classification
Abacavir belongs to the nucleoside reverse transcriptase inhibitor, or NRTI, group of antiretroviral drugs.
NRTIs interfere with reverse transcriptase, an enzyme involved in converting viral RNA-derived information into DNA. Abacavir requires intracellular metabolic activation before producing its main pharmacological effect.
How Does Abacavir Work?
The mechanism of action can be understood in three main steps.
Step 1: Intracellular Activation
After entering cells, abacavir undergoes metabolic conversion to carbovir triphosphate, its pharmacologically active metabolite.
Step 2: Competition with dGTP
Carbovir triphosphate acts as an analogue of the naturally occurring nucleotide deoxyguanosine triphosphate, commonly abbreviated as dGTP.
It competes with dGTP for HIV reverse transcriptase.
Step 3: Viral DNA Chain Termination
When carbovir triphosphate is incorporated into viral DNA, further DNA elongation is interrupted, resulting in chain termination.
Research published in Biochemistry has examined the interaction of carbovir triphosphate with HIV-1 reverse transcriptase and its role in DNA-chain termination.
Abacavir → Carbovir triphosphate → Reverse transcriptase inhibition → Viral DNA chain termination
Abacavir Chemical Structure and Pharmaceutical Identity
Abacavir is chemically distinct from naturally occurring nucleosides because it contains a carbocyclic ring system.
According to PubChem, the IUPAC name of abacavir is:
[(1S,4R)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]cyclopent-2-en-1-yl]methanol
Important Structural Features
- A purine-like heterocyclic system
- A cyclopropylamino substituent
- A carbocyclic cyclopentene ring
- A hydroxymethyl functional group
- Defined stereochemistry at key carbon atoms
Abacavir vs Abacavir Sulphate
Abacavir and abacavir sulphate are closely related terms, but they describe different pharmaceutical forms.
| Property | Abacavir | Abacavir Sulphate |
|---|---|---|
| Type | Active molecular entity | Pharmaceutical salt form |
| Formula | C14H18N6O | (C14H18N6O)2·H2SO4 |
| Molecular Weight | 286.33 g/mol | Approximately 670.8 g/mol |
| Academic Focus | Medicinal chemistry and pharmacology | Formulation and pharmacopoeial study |
| Pharmacopoeial Relevance | Active drug identity | Listed in the Indian Pharmacopoeia |
The Indian Pharmacopoeia identifies Abacavir Sulphate as a monograph substance, while the Indian Pharmacopoeia Commission maintains reference material used for pharmaceutical analysis and quality control.
Development and History of Abacavir
Abacavir emerged from intensive antiretroviral drug research during the 1990s.
A 1998 review by Foster and Faulds described abacavir as a nucleoside analogue reverse transcriptase inhibitor with activity against HIV isolates.
Another publication by Roberts documented the development of the synthetic route to abacavir and highlighted collaboration between academic researchers and the pharmaceutical industry.
By the late 1990s, abacavir had progressed through clinical development and became associated with the trade name Ziagen.
The development of abacavir provides students with a useful medicinal chemistry case study. It demonstrates how a drug candidate progresses through chemical synthesis, pharmacological evaluation, formulation, regulatory assessment, and commercial manufacture.
Abacavir Generic Name vs Trade Name
Understanding the difference between generic and trade names helps prevent confusion in academic and pharmaceutical writing.
| Generic / INN | Trade / Brand Name |
|---|---|
| Abacavir | Ziagen |
| Active pharmaceutical ingredient | Commercial brand name |
| Used in scientific and academic writing | Used mainly in product labelling and branding |
| Common in pharmacology and pharmacopoeial references | Associated with a marketed pharmaceutical product |
Abacavir is the International Nonproprietary Name used when discussing the active pharmaceutical ingredient.
Ziagen is a recognised trade name associated with abacavir. In scientific writing, the generic name “abacavir” is generally preferred unless the discussion specifically concerns a branded product.
Key Points for Students
- Drug class: Nucleoside reverse transcriptase inhibitor (NRTI)
- Active metabolite: Carbovir triphosphate
- Main enzyme target: HIV reverse transcriptase
- Key molecular effect: Viral DNA chain termination
- Generic name: Abacavir
- Common pharmaceutical form: Abacavir sulphate
- Molecular formula: C14H18N6O
- PubChem CID: 441300
- Trade name example: Ziagen
Frequently Asked Questions About Abacavir
What is abacavir and how does it work?
Abacavir is a nucleoside reverse transcriptase inhibitor. Inside cells, it is converted to carbovir triphosphate, which competes with natural nucleotides for HIV reverse transcriptase and contributes to viral DNA chain termination.
Is abacavir an NRTI?
Yes. Abacavir is classified as a nucleoside analogue reverse transcriptase inhibitor, commonly abbreviated as NRTI.
What is the molecular formula of abacavir?
The molecular formula of abacavir free base is C14H18N6O. Its molecular weight is approximately 286.33 g/mol.
What is the difference between abacavir and abacavir sulphate?
Abacavir refers to the active molecular entity, while abacavir sulphate is a pharmaceutical salt form. Abacavir Sulphate is also recognised in the Indian Pharmacopoeia.
What is the trade name of abacavir?
Ziagen is one recognised trade name associated with abacavir. The generic name remains abacavir.
Why is HLA-B*5701 associated with abacavir?
HLA-B*5701 is an important pharmacogenetic marker associated with an increased risk of abacavir hypersensitivity reactions. Its relationship with abacavir is widely discussed in pharmacogenomics and clinical pharmacology literature.
References
- NCBI PubChem. Abacavir, PubChem CID 441300.
- Foster RH, Faulds D. Abacavir. Drugs. 1998. PMID: 9585869.
- Roberts SM. Development of the route to the new anti-AIDS drug abacavir. IDrugs. 1998. PMID: 16196482.
- NCBI PubMed. Research on the molecular mechanism of HIV-1 reverse transcriptase inhibition by carbovir triphosphate.
- Indian Pharmacopoeia Commission. Abacavir Sulphate monograph and reference substance.
- NIH ClinicalInfo. Abacavir drug information and pharmacology resources.
This article is intended solely for educational and academic purposes. It is not intended for diagnosis, prescribing, treatment, or other clinical decision-making.
